The collaboration will leverage Sangamo’s propriety genome regulation technology, zinc finger protein transcription factors (ZFP-TFs), aiming to upregulate the expression of key genes involved in neurodevelopmental disorders. This evidence concerns the gene ZKSCAN7 and neurodevelopmental disorder.